Bengt Ingemar Samuelsson

Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden.

Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland.

Life Science Analytics, Inc. is a research firm headquartered in Scranton, Pennsylvania. They are a subsidiary of Datamonitor Ltd. and their ultimate parent is Informa Plc (LON: INF) in Great Britain. The firm provides comprehensive pipeline and financial information on more than 13,000 biomedical companies worldwide. Their data and research products serve executives in the pharmaceutical, biotech, and financial industries.

French Academy of Sciences engages in protection of spirit of French scientific research. The firm offers science teaching, transmitting knowledge, international collaboration and advice. The company was founded by Jean-Baptiste Colbert in 1666 and is headquartered in Paris, France.

RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden.

LTB4 Sweden AB engages in research and product development related to antimicrobial and anti-inflammatory substances through its subsidiaries. The company was founded by Bengt Ingemar Samuelsson on February 26, 2004 and is headquartered in Stockholm, Sweden.

NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden.